medical-devices is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Anne Lockwood, the most common co-covered peer. Their average consequence score of 5 runs below the beat's 5.6 for that window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about ClearView Wealth
medical-devices is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Anne Lockwood, the most common co-covered peer. Their average consequence score of 5 runs below the beat's 5.6 for that window. They are less corroborated than the beat average, carrying 4 original sources each against 4.7 for the same window. ClearView Wealth appears in 1 tracked Healthcare story from February 26, 2026.
Stories tracked
1
Sources per story
4
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 41 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering ClearView Wealth. Shared-story counts are live from our verified record — not editorial picks.
Genetic Signatures (ASX:GSS) reported a modest revenue increase for H1 FY26 but warned of unsustainable cash burn and declining gross margins. The company is now pivoting toward aggressive cost-cutting and operational restructuring to stabilize its financial position.